Introduction
Francisella tularensis (FT), the causative agent of tularemia, produces an acute infection in vertebrates, including humans, with clinical symptoms such as acute fever and inflammation of the respiratory system [1] . Moreover, because of its extreme virulence, ease of aerosol dissemination, and low infective dose (as few as 10 organisms), FT is considered as to be a potential biological weapon and bioterrorism agent [2] . The bacterium is classified as a Category A agent by the Centers for Disease Control and Prevention [3] .
Several vaccine candidates, including live vaccines, that can impart effective protection against FT are under development [2] . However, no vaccine against tularemia is currently available for human use. An attenuated live vaccine strain (LVS) has been developed and has shown protection in animal studies, but it has not yet been licensed for public use by the US Food and Drug Administration owing to safety concerns [3] . Tul4, an outer membrane protein component of FT, is known to be an immunogen that stimulates lymphocyte and CD4+ T-cell proliferation, and has a partial protective effect against intranasal challenges with lethal doses of LVS [4, 5] . Another outer membrane protein component, FopA, when incorporated within liposomes and administered to mice, was shown to elicit FopA-specific antibodies and protection against intradermal and intranasal challenges with lethal doses of LVS [5, 6] . These studies have certainly contributed to a greater understanding of the immune mechanisms and the development of vaccine candidates; however, the relevance of the results obtained from experimental animal models to the immune responses in humans is difficult to evaluate.
Although mouse models are most common in vaccine evaluations, this animal model has limitations because the immune response to and survival from FT infections are different for each mouse strain. In particular, C57BL/6 mice are known to be more susceptible than BALB/c mice to FT infection, and histopathological damage is more severe in the former than in the latter [7, 8] . Therefore, an animal model is needed that can predict human immune responses to vaccines beyond differences between strains and species.
Humanized mice (hu-mice) have been used recently to study specific diseases of the human immune system, such as those caused by the human immunodeficiency virus and the Epstein-Barr virus [9, 10] . Moreover, it has been reported that the antibody produced by the humoral response to Dengue virus infection in hu-mice possesses functional similarity to the antibody isolated from human patients, and could neutralize the Dengue virus [11] . Therefore, humice bearing the human immune system could potentially bridge the gap between animal models and human research, and this model could be optimized to assess vaccine efficacy with regard to the human immune system.
In the present study, we immunized hu-mice with recombinant Tul4 and FopA (rTul4 and rFopA), and then challenged the mice with a LVS. In previous studies, we and other researchers had demonstrated rTul4 and rFopA to be excellent vaccine candidates for inducing cellular and humoral immune responses [12] . In this study, we used rTul4 and rFopA to evaluate the potential of hu-mice as a suitable animal model for vaccine development.
Materials and Methods

Production of Recombinant Tul4 and FopA Proteins
The pET28b vector (Novagen, USA) was cloned respectively with the Tul4 and FopA genes, using both N-terminal and Cterminal six-histidine tags. Vector-Tul4 and vector-FopA were then respectively expressed in Rosetta 2(DE3)pLysS Competent cells (Novagen, USA) and cultured in Luria-Bertani medium. After sonication of the harvested cells, the inclusion bodies were collected from the lysates by centrifugation. These insoluble pellets were resolved in 6 M guanidine-HCl buffer, and purified by Ni-NTA affinity chromatography. The identity of the expressed rTul4 and rFopA was examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie Brilliant Blue staining. The concentration of each recombinant protein was estimated by the Bradford method.
Mice
NOD.Cg-Prkdc
/SzJ (NSG) mice were purchased from the Jackson Laboratory (USA). The mice were bred and maintained under specific-pathogen-free condition at the animal facility in the College of Veterinary Medicine, Seoul National University. All experiments on animals were approved by the Seoul National University Institutional Animal Care and Use Committee (SNU-150202-1).
Establishment of Humanized Mice
Five-week-old NSG mice were intraperitoneally injected with busulfan (30 mg/kg body weight; Sigma Chemical Co., USA). After 24 h, the busulfan-conditioned mice were inoculated with 1 × 10 5 human cord blood CD34+ cells (STEMCELL, Canada) via the tail vein.
Analysis of Human Cell Engraftment
At 6 weeks after transplantation of the human CD34+ cells, mice were anesthetized with a mixture of xylazine (5 mg/mg; Bayer Korea, Korea) and alfaxan (60 mg/kg; Careside, Korea), following which blood samples from the retroorbital plexus were collected into heparinized capillary tubes. After removal of the red blood cells with ammonium-chloride-potassium lysis buffer (Lonza, USA), the samples were stained with the following antihuman antibodies: hCD45-fluorescein isothiocyanate, hCD19-phycoerythrin, and hCD3-allophycocyanin (eBioscience, USA). Flow cytometry analysis was performed using a FACS Aria II device (BD Biosciences, USA) equipped with FACS Diva software, installed at the National Center for Inter-University Research Facilities at Seoul National University.
Vaccination of the Humanized Mice
The hu-mice were immunized subcutaneously with the rTul4 (40 µg/ml) and rFopA (20 µg/ml) combination or phosphatebuffered saline (PBS) on Days 0, 14, and 28. Blood samples were collected before the immunization and at 2-week intervals following the final injection, and the sera were separated by centrifugation and stored at -70 o C. The hu-mice were anesthetized with a mixture of xylazine (5 mg/mg) and alfaxan (60 mg/kg) for the blood collections.
Humoral Immune Response
The concentrations of human IgM and IgG in the hu-mice were quantified through use of a commercial ELISA kit (Human IgM and IgG Ready-SET-Go! ELISA; eBioscience), following the manufacturer's procedures. In brief, Corning Costar 96-well plates were coated overnight at 4 o C with anti-human IgM and IgG monoclonal antibodies, respectively. After washing with PBS, the coated plates were blocked for 2 h with bovine serum albumin. Diluted serum samples were then added and the plates were left to stand for 2 h at room temperature. Known concentrations of human IgM and IgG were then applied, respectively, for use as standard curves. The plates were then incubated with horseradish peroxidase-conjugated anti-human-IgM and IgG monoclonal antibodies for 1 h at room temperature and thereafter developed with tetramethylbenzidine solution. After 15 min, the reactions of the substrate were stopped with 2N H 2 SO 4 solution, and the plates were read at 450 nm using an Epoch microplate reader (BioTek, USA).
The concentrations of antigen-specific IgM and IgG were measured by the ELISA method described above, but with slight modification, in that the 96-well plates were coated overnight at 4 o C with 4 µl/ml synthetic rTul4 and rFopA, respectively.
Challenge Test
The FT LVS was cultured on cystine heart agar (Difco, Becton Dickinson, USA) with 9% sheep blood at 37 o C for 48 h, and was suspended in PBS for the inoculations. Hu-mice (immunized three times at 2-week intervals) and control hu-mice were challenged intranasally with a LVS (1 × 10 3 CFU), and were then monitored daily for 2 weeks for signs of mortality.
Histopathological Analysis
After the challenge test, the spleens from the hu-mice were fixed in 10% neutral-buffered formalin and embedded in paraffin. The tissue paraffin blocks were sectioned into 3 µm slices, deparaffinized, rehydrated, and stained with hematoxylin and eosin (H&E).
Additional sections were deparaffinized and autoclaved for 20 min for antigen retrieval in a target retrieval solution (Dako, USA). The sections were washed with 0.025% PBST, blocked with normal horse serum for 1 h, and incubated overnight at 4 o C with monoclonal mouse anti-human CD3 antibody (diluted of 1:50; eBioscience). On the following day, after washing the slides, goat anti-mouse Alexa Fluor 594 (diluted 1:1,000; Invitrogen, USA) was applied to the sections for 1 h. After washing again, the slides were mounted with VECTASHIELD Antifade Mounting Medium with 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, USA).
Statistical Analyses
Statistical analyses were performed using Prism GraphPad ver. 6. Repeated measures analysis of variance followed by the Bonferroni post-hoc test was used to analyze the data of total IgM and total IgG. The Mann-Whitney U test was applied for comparison of differences in the antigen-specific immunoglobulins. All data are expressed as the mean of samples ± standard error.
Results
Cloning, Expression, and Purification of rTul4 and rFopA
In this study, we cloned the codon-optimized recombinant Tul4 and FopA genes of FT individually into the pET-28b vector, expressed them in E. coli cells, and then purified the proteins using Ni-NTA agarose. The purity of rTul4 (20.8 kDa) and rFopA (46 kDa) and their identity were monitored by SDS-PAGE, Coomassie Brilliant Blue staining (Figs. 1A and 1C) , and western blotting (Fig. 1B) , respectively.
Human Specific Immune Response after Immunization in Humanized Mice
Human cord blood CD34+ cells were introduced into 5- Fig. 1 . Cloning, expression, and purification of rTul4 and rFopA. week-old NSG mice via the tail vein. The establishment of a human immune system in the resulting hu-mice was confirmed by assessing the production of human T and B cells (Fig. S1 ). Populations of human T and B cells were detected in the blood serum of the mice, and showed a continuous increase, reaching peak levels at 6 and 8 weeks after transplantation. Serum samples from hu-mice immunized three times at 2-week intervals were collected at each sampling time point, and the levels of antibodies were measured using ELISA. As shown in Fig. 2A , total human IgG was detectable at 4 weeks after the first immunization, and increased progressively until 6 weeks. On the contrary, no IgG was detected in the control hu-mice group at all sampling time points. In addition, the total human IgM levels showed a consistent increase with each subsequent boosting. A significant difference in the antibody levels was found between the two groups at 6 weeks after immunization. Unlike the total human IgG levels, total human IgM levels were detectable in the control group at all sampling time points.
To confirm the functional efficacy of the human antibodies produced in hu-mice, the levels of specific IgG and IgM against rTul4 and rFopA were measured in the blood serum at 6 weeks, when the antibody levels had reached a peak. Although it is difficult to quantify the amount of specific antibody, owing to the lack of a standard antibody against Tul4 and FopA, the production of specific IgG and IgM was confirmed by the significant differences in the absorbance values of serum samples between the two groups in the ELISA (Fig. 2B) . In the immunized mice, Tul4-and FopA-specific IgM were dramatically increased relative to the control mice levels, whereas the Tul4-specific IgG was poorly produced even though its absorbance was significantly higher than that in the control mice.
Partial Protection against LVS in Humanized Mice
Immunized with rTul4 and rFopA
To determine whether the human antibodies induced in the blood could protect against a lethal dose of LVS (1 × 10 3 CFU), the hu-mice were challenged with an intranasal injection of LVS at 8 weeks after immunization. Owing to the potential virulence of the LVS, the challenge and survival experiments were performed in a Biosafety Level 3 facility. The survival curves and median survival time (MST) were measured after the LVS challenge (Fig. 3) . In this experiment, all animals in both the control and the rTul4-and rFopA-immunized groups showed a progressive loss of body weight with anorexia. Similar survival curves were observed for both these groups. However, the immunized group had a longer MST (9 days) than the control group (7 days).
To confirm the effect of intranasal challenge in the immunized and control hu-mice, the lung tissues were analyzed. Although alveoli and parenchyma were filled with macrophages, lymphocytes, and neutrophils in both groups, the alveolar structure remained in the immunized hu-mice compared with the controls (Fig. 4) . Moreover, in the control group, the alveolar septa were severely thickened, and cell debris was observed together with severe necrosis. This result shows that the lungs were less damaged by intranasal LVS challenge in immunized humice than in the control hu-mice.
We further confirmed the effect of rTul4 and rFopA on immune cells that were the main targets against FT, for which the spleen tissues from the immunized and control hu-mice, post LVS challenge, were prepared for histopathological analysis. Although rTul4 and rFopA immunization did not increase the survival rate of hu-mice from LVS challenge, there was higher splenocyte survival in the immunized hu-mice than in the controls (Fig. 5) . In addition, most of the splenocytes in the control group were undergoing apoptosis, and it was difficult to observe any normal ones. Relatively normal splenocytes that were resistant against the LVS and retained a normal splenic structure, including white pulp and red pulp, were observed in the immunized hu-mice only.
Next, to verify whether the splenocytes that had survived in the hu-mice were of human or mouse origin, the cells were stained with human CD3 antibody. As shown in Fig. 6 , CD3+ human T cells over DAPI-positive cells (staining live nuclei) were identified in the immunized hu-mice. Taken together with the histopathological results, we conclude that rTul4 and rFopA immunization supports human T-cell survival in the spleens of hu-mice.
Discussion
Tul4 and FopA are representative outer membrane components of FT. The proteins are exposed to the surface and are most accessible to antibodies, indicating their high potential as candidates for a protective vaccine [6] . Therefore, we evaluated the possibility of a Tul4 and FopA combination as a vaccine candidate in mice with a human immune system.
In our study, we confirmed the elicitation of T and B cells between 6 and 8 weeks in mice bearing CD34+ cells, indicating that a stable hu-mouse model had been established. In addition, the human total IgM and total IgG levels in the hu-mice were significantly increased after 2 weeks of final immunization. After 6 weeks, when humoral immunity was at its maximum, antigen-specific human IgM and IgG were detected. These results mean that the human immune system had been well developed by the human cord blood CD34+ cell graft in the hu-mice. In the human immune system, IgM responds most rapidly to exposure to external antigens, whereupon IgG increases rapidly to remove the antigen. We have shown that an increase in IgM levels preceded the increase in IgG levels in a manner similar to the human immune response. Interestingly, total IgG was not detected in the control humice, and its increase in the immunized hu-mice was dependent on the immunizations. These results indicate that human IgG was induced in hu-mice by rTul4 and rFopA stimulation, suggesting that the immune system of hu-mice is almost similar to that of humans.
The production of antigen-specific human IgG in hu-mice was poor compared with antigen-specific human IgM, consistent with the results of previous studies [13, 14] . Several possibilities have been suggested for the insufficiency of specific IgG production in hu-mice, including the lack of interaction between B and T cells due to major histocompatibility complex mismatches [15] and the result of a series of processes involving the absence of interleukin-2 and the high susceptibility of T cells to apoptosis [16] . In contrast to a previous study in which FopA-specific IgG was identified, this study did not detect it in the hu-mice [6] . The reason for this is not clear, but it may be related to an insufficient induction of the humoral immune response resulting from transplantation of the human immune system into the mouse immune system, and the absence of an appropriate immune environment, such as human cytokines and secondary lymphoid organs for human immune cells [17] [18] [19] . Therefore, in future studies, it would be necessary to develop a hu-mouse capable of efficiently producing an antigen-specific antibody, including a neutralizing antibody.
FT is a highly contagious pathogen, and because of its risk, the challenge tests were conducted at an approved Biosafety Level 3 facility. There was no statistically significant difference in the survival rate between the immunized and control groups, but the MST showed an increase tendency in the immunized group. Several studies have shown that vaccine candidates made up of one or two subunits, such as DnaK, Tul4, and FopA, have a partial protective effect against the lethal dose of LVS and are less immunogenic than live attenuated vaccines [4, 6, 20] . In line with these studies, our challenge results suggest a partial protective effect of the subunit vaccine candidate in the hu-mouse model against the LVS.
The efficacy of these immunization candidates in hu-mice was further confirmed by examining the histopathologic changes in the lungs and the immune responses in the spleen. It was found that immunized hu-mice had partially normal alveolus structures. In addition, the surviving splenocytes had retained a normal white pulp structure, and these immunized hu-mice had a greater number of surviving human CD3+ immune cells than the control mice. Therefore, although the efficacy of rTul4 and rFopA was insufficient to produce a 100% survival rate of the humice, these vaccine candidates nevertheless were able to partially defend the CD3 cells against the LVS. In particular, the survival of the T cells in the spleen is presumed to be caused by rTul4 and rFopA, whereupon the immune cells could be protected from the LVS infection and avoided apoptosis. Cowley and Elkins [21] have reported that the Tcell subpopulation isolated from splenocytes inhibits and regulates the intracellular growth of the LVS. Thus, the support provided by rTul4 and rFopA toward T-cell survival suggests their potential for use as an adjuvant for the suppression and clearance of LVS infections. Above all, the survival of human T cells, not mouse T cells, was confirmed in the mice reconstituted with human immune cells, confirming that the experimental results obtained in the biological systems of these mice closely reflect the human immune system.
In conclusion, we confirmed that human CD34+ hematopoietic cells can be stably engrafted in mice, for construction of the human immune system. The immune responses elicited by the rTul4 and rFopA cocktail were successfully evaluated in this system, showing the feasibility of the hu-mouse model for use in the evaluation of tularemia vaccine candidates. The spleen slides were stained with anti-human CD3 antibody (B and E) and with DAPI for verification of nuclei (A and D). C and F show a merged image of A and B, and D and E, respectively. Scale bar, 50 µm.
